MAPT and Parkinson disease: In the framework of Precision Medicine, the patient’s assessment is aimed at not only providing a clinical diagnosis by proper in-vivo biofluid or neuroimaging techniques measuring disease-specific neuropathological species in the brain of PD or AD patients (e.g., amyloid-beta and tau in AD patients), but also to use reliable and valid biomarkers accounting for neurobiological, neuroanatomical, and neurophysiological underpinnings of the individual clinical manifestations along the disease course.